ANN ARBOR STAGE II B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE II B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE II B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE II B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Tiny radiation dose may tame eye lymphoma with fewer side effects
Disease control OngoingThis study tests whether an ultra low dose of radiation (4 Gy) can safely control slow-growing B-cell lymphoma or mantle cell lymphoma that has spread to the eye socket. About 50 adults with stage I to IV disease will receive this targeted radiation. The goal is to shrink or stop…
Matched conditions: ANN ARBOR STAGE II B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
Immunotherapy-Chemo combo shows promise in aggressive lymphoma trial
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. About 30 participants will receive the combination, followed by a short course of nivolumab…
Matched conditions: ANN ARBOR STAGE II B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC